Ticagrelor

Nature Reviews Drug Discovery

Volumn 10, Issue 4, 2011, Pages 255-256

  Huber, Kurt ^a   Hamad, Bashar ^b   Kirkpatrick, Peter ^c  

^a WILHELMINEN HOSPITAL   (Austria)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BRILIQUE; CLOPIDOGREL; PRASUGREL; TICAGRELOR; UNCLASSIFIED DRUG; ADENOSINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ARTICLE; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LOADING DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; ADULT; ATHEROSCLEROSIS;

ACUTE CORONARY SYNDROME; ADENOSINE; ADULT; ATHEROSCLEROSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THROMBOSIS;

EID: 79953665779     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3418     Document Type: Article

References (17)

1. Michelson, A. D. Antiplatelet therapies for the treatment of cardiovascular disease. Nature Rev. Drug Discov. 9, 154-169 (2010).
2. Huber, K. et al. Prasugrel. Nature Rev. Drug Discov. 8, 449-450 (2009).
3. Springthorpe, B. et al. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg. Med. Chem. Lett. 17, 6013-6018 (2007). (Pubitemid 47446193)
4. van Giezen, J. J. & Humphries, R. G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31, 195-204 (2005). (Pubitemid 40605194)
5. European Medicines Agency (EMA). European Public Assessment Report - Brilique. EMA website [online], http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/001241/WC500100494.pdf (2011).
6. Gurbel, P. A. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120, 2577-2585 (2009).
7. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
8. James, S. et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur. Heart J. 31, 3006-3016 (2010).
9. James, S. et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122, 1056-1067 (2010).
10. Cannon, C. P. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375, 283-293 (2010).
11. Held, C. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J. Am. Coll. Cardiol. 57, 672-684 (2011).
12. Wallentin, L. et al. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Thromb. Haemost. 11 Mar 2011 (doi:10.1160/TH11-03-0162).
13. Huber, K. Genetic variability in response to clopidogrel therapy: clinical implications. Eur. Heart J. 31, 2974-2976 (2010).
14. Wallentin, L. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376, 1320-1328 (2010).
15. IMS MIDAS, MAT Q4 2010 (IMS Health, 2010).
16. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
17. Clark, M. et al. Deutsche Bank. Global Markets Research; AstraZeneca (27 Jan 2011).